Stifel Nicolaus Initiates Biotie Therapies At Buy

Analysts at Stifel Nicolaus initiated coverage on

with a Buy rating. The target price for Biotie Therapies is set to $30. Biotie Therapies' shares rose 4.02 percent to $19.13 in pre-market trading.